OANDP-L
  • Login
No Result
View All Result
The O&P EDGE
  • PECOS
  • Magazine
    • Subscription
    • Current Issue
    • Issue Archive
    • News Archive
    • Product & Service Directory
    • Advertising Information
    • EDGE Flipbooks
  • O&P Jobs
    • Find a Job
    • Post a Job
  • EDGE Advantage
    • EA Homepage
    • EA Data
  • O&P Facilities
  • Resources
    • Product & Service Directory
    • Calendar
    • Contact
    • About Us
    • O&P Library
    • The Guide
    • Custom Publications
    • Advertising Information
    • EDGE Direct
    • Amplitude Media Group
  • PECOS
  • Magazine
    • Subscription
    • Current Issue
    • Issue Archive
    • News Archive
    • Product & Service Directory
    • Advertising Information
    • EDGE Flipbooks
  • O&P Jobs
    • Find a Job
    • Post a Job
  • EDGE Advantage
    • EA Homepage
    • EA Data
  • O&P Facilities
  • Resources
    • Product & Service Directory
    • Calendar
    • Contact
    • About Us
    • O&P Library
    • The Guide
    • Custom Publications
    • Advertising Information
    • EDGE Direct
    • Amplitude Media Group
No Result
View All Result
The O&P EDGE Magazine
No Result
View All Result
Home News

Drug Cuts Breast Cancer Recurrance 25%

by The O&P EDGE
June 3, 2009
in News
0
SHARES
9
VIEWS
Share on FacebookShare on Twitter

The Breast International Group (BIG), a Belgian nonprofit research-sharing network, in collaboration with pharmaceutical giant Roche has announced the release of research indicating that the drug Herceptin (generic name trastuzumab) may give survivors of HER2-positive early breast cancer a 25 percent reduction in the risk of their cancer’s recurring. Furthermore, according to BIG, “women with HER2-positive early breast cancer continue to benefit from Herceptin (trastuzumab) several years after treatment completion and as a result enjoy a longer life disease free.”

The data was derived from the HERA (HERceptin Adjuvant) study, an international phase III study conducted as a collaboration between BIG and Roche. The study, with over 5000 patients enrolled, is still currently assessing the benefits of adjuvant Herceptin treatment in women with HER2 positive early breast cancer. The HERA study’s primary endpoint is disease-free survival (DFS); its secondary endpoint is overall survival (OS) and cardiac safety.

In the study, patients were treated for one year with Herceptin and followed up for four years. In data presented at the Primary Therapy in Early Breast Cancer conference in St. Gallen, Switzerland, women treated with Herceptin had a 25 percent reduction in the risk of their cancer coming back compared to women who did not receive Herceptin, and after four years of medical observation on average, almost 90 percent of the Herceptin-treated women were still alive. In addition to the significant treatment benefit, this analysis confirmed the long-term safety profile of Herceptin, with good cardiac safety and tolerability maintained throughout the four-year follow-up period.

“These data are extremely important for the treatment of breast cancer,” commented Martine Piccart, MD, PhD, lead investigator of the HERA study and chair of BIG. “HERA is the first of the four large Herceptin studies in early HER2-positive breast cancer to substantiate the long-term benefit derived from one year of treatment.”

“These important long-term results from the HERA trial reinforce that women with this aggressive type of cancer have the best chance of cure with Herceptin,” said William M. Burns, CEO of Roche’s Pharmaceuticals Division.

Historically, HER2-positive breast cancer has been associated with a poor prognosis, but the first analysis of the HERA trial, released in 2005, established significant benefits in terms of lowering the risk of cancer returning (disease-free survival).

Related posts:

  1. Options in Post-Mastectomy Prosthetic Care
  2. Bra Ladies? Not on Your Life!
  3. A Lifelong Connection: The Patient-Provider Relationship in Post-mastectomy Care
  4. Post-Mastectomy Fitters Find Their Niche in the Breast Cancer Community
Previous Post

Amputee Gets Rare Second Chance to Sue

Next Post

Trumper Wins Yasukawa Scholarship

Next Post

Trumper Wins Yasukawa Scholarship

Linkedin X-twitter Facebook

 SUBSCRIBE FOR FREE

 

RECENT NEWS

Get unlimited access!

Join EDGE ADVANTAGE and unlock The O&P EDGE's vast library of archived content.
SUBSCRIBE TODAY

O&P JOBS

Multiple Locations

CERTIFIED ORTHOTIST or PROSTHETIST/ORTHOTIST 

Central

Multiple Locations- Resident Prosthetist / Board Eligible Prosthetist CP/LP

Central

Prosthetic Technician

The O&P EDGE Magazine
 
Required 'Candidate' login to applying this job. Click here to logout And try again
 

Login to your account

  • Forgot Password? | Sign Up

Reset Password

  • Already have an account? Login

Enter the username or e-mail you used in your profile. A password reset link will be sent to you by email.

Signup to your Account

  • By clicking checkbox, you agree to our Terms and Conditions and Privacy Policy

    Already have an account? Login

Close
No Result
View All Result
  • PECOS
  • MAGAZINE
    • SUBSCRIBE
    • CURRENT ISSUE
    • ISSUE ARCHIVE
    • NEWS ARCHIVE
    • PRODUCTS & SERVICES DIRECTORY
    • ADVERTISING INFORMATION
  • O&P JOBS
    • FIND A JOB
    • POST A JOB
  • EDGE ADVANTAGE
    • EA Homepage
    • EA Data
  • FACILITIES
  • RESOURCES
    • PRODUCTS & SERVICES DIRECTORY
    • CALENDAR
    • CONTACT
    • ABOUT US
    • O&P LIBRARY
    • THE GUIDE
    • CUSTOM PUBLICATIONS
    • ADVERTISING INFORMATION
    • EDGE DIRECT
    • AMPLITUDE
  • OANDP-L
  • LOGIN

© 2025 The O&P EDGE

Are you sure want to unlock this post?
Unlock left : 0
Are you sure want to cancel subscription?
 

Account Activation

Before you can login, you must activate your account with the code sent to your email address. If you did not receive this email, please check your junk/spam folder. Click here to resend the activation email. If you entered an incorrect email address, you will need to re-register with the correct email address.

 

© 2024 The O&P EDGE

  • About
  • Advertise
  • Contact
  • EDGE Advantage
  • OANDP-L
  • Subscribe

CONTACT US

866-613-0257

[email protected]

201 E. 4th St.
Loveland, CO 80537

The most important industry news and events delivered directly to your inbox every week.

  • About
  • Advertise
  • Contact
  • EDGE Advantage
  • OANDP-L
  • Subscribe

© 2025 The O&P EDGE

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
The O&P EDGE Magazine
 
Required 'Candidate' login to applying this job. Click here to logout And try again
 

Login to your account

  • Forgot Password? | Sign Up

Reset Password

  • Already have an account? Login

Enter the username or e-mail you used in your profile. A password reset link will be sent to you by email.

Signup to your Account

  • By clicking checkbox, you agree to our Terms and Conditions and Privacy Policy

    Already have an account? Login

Close
No Result
View All Result
  • PECOS
  • MAGAZINE
    • SUBSCRIBE
    • CURRENT ISSUE
    • ISSUE ARCHIVE
    • NEWS ARCHIVE
    • PRODUCTS & SERVICES DIRECTORY
    • ADVERTISING INFORMATION
  • O&P JOBS
    • FIND A JOB
    • POST A JOB
  • EDGE ADVANTAGE
    • EA Homepage
    • EA Data
  • FACILITIES
  • RESOURCES
    • PRODUCTS & SERVICES DIRECTORY
    • CALENDAR
    • CONTACT
    • ABOUT US
    • O&P LIBRARY
    • THE GUIDE
    • CUSTOM PUBLICATIONS
    • ADVERTISING INFORMATION
    • EDGE DIRECT
    • AMPLITUDE
  • OANDP-L
  • LOGIN

© 2025 The O&P EDGE

Are you sure want to unlock this post?
Unlock left : 0
Are you sure want to cancel subscription?
 

Account Activation

Before you can login, you must activate your account with the code sent to your email address. If you did not receive this email, please check your junk/spam folder. Click here to resend the activation email. If you entered an incorrect email address, you will need to re-register with the correct email address.